Qian L. · Wang Y. · Xiong Y. · Ren H. · Liu S. · Chen D. · Liu Y.

Author affiliations

Department of Clinical Laboratory, Suizhou Hospital, Hubei University of Medicine, Suizhou, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Received: July 19, 2022
Accepted: February 21, 2023
Published online: April 11, 2023

Number of Print Pages: 13
Number of Figures: 6
Number of Tables: 2

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Abstract

Introduction: In view of the vital implication of long noncoding RNAs in tumorigenesis, we possess the aim to determine the action effects and mechanisms of LINC01002 in prostate cancer (PCa). Methods: Expression level of LINC01002, miR-650, or filamin A (FLNA) in PCa tissues and cells was assessed using quantitative real-time PCR or Western blotting. Cell proliferative and migratory capacities were investigated by Cell Counting Kit-8 (CCK-8) and wound healing assays. Cell apoptosis was investigated by the levels of Bax and Bcl-2. Xenograft models were constructed to testify the role of LINC01002 in vivo. The anticipated binding of miR-650 to LINC01002 or FLNA was confirmed by dual-luciferase reporter or RNA binding protein immunoprecipitation assays. Results: Relatively poor expression of LINC01002 and FLNA, and high expression of miR-650 were identified in PCa tumor specimens and cells. Ectopic LINC01002 expression restrained PCa cell proliferation/migration and provoked apoptosis in vitro, and blocked solid tumor growth in Xenograft models. MiR-650 was directly targeted by LINC01002, and it also directly bound to FLNA. MiR-650 reintroduction in PCa cells overexpressing LINC01002 or FLNA partly reversed the anticancer effects of LINC01002 or FLNA overexpression, thus recovering PCa cell proliferation/migration and repressing apoptosis. Conclusion: LINC01002 deregulation was linked to PCa development. LINC01002 exerted potential anticancer effects in PCa via targeting the miR-650/FLNA pathway, which, at least in part, provided a basis for the involvement of LINC01002 as a therapeutic target in PCa.

© 2023 S. Karger AG, Basel

References Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–49. Lee D, Choi SK, Park J, Shim M, Kim A, Lee S, et al. Comparative analysis of oncologic outcomes for open versus robot-assisted radical prostatectomy in high-risk prostate cancer. Korean J Urol. 2015 Aug;56(8):572–9. Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, et al. Long-term outcomes following radiation therapy for prostate cancer patients with lymph node metastases at diagnosis treated with and without surgery. Am J Clin Oncol. 2016 Apr;39(2):167–72. Kgatle MM, Kalla AA, Islam MM, Sathekge M, Moorad R. Prostate cancer: epigenetic alterations, risk factors, and therapy. Prostate cancer. 2016;2016:5653862. Perdomo HAG, Zapata-Copete JA, Sanchez A. Molecular alterations associated with prostate cancer. Cent Eur J Urol. 2018;71(2):168–76. Huang K, Tang Y. SChLAP1 promotes prostate cancer development through interacting with EZH2 to mediate promoter methylation modification of multiple miRNAs of chromosome 5 with a DNMT3a-feedback loop. Cell Death Dis. 2021 Feb 15;12(2):188. Lu S, Wang T, Zhang G, He QY. Understanding the proteome encoded by “non-coding RNAs”: new insights into human genome. Sci China Life Sci. 2020 Jul;63(7):986–95. Bian Z, Ji W, Xu B, Huang W, Jiao J, Shao J, et al. The role of long noncoding RNA SNHG7 in human cancers (Review). Mol Clin Oncol. 2020 Nov;13(5):45. Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T, Calin GA. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014 Jun;65(6):1140–51. Wang M, Zhou L, Yu F, Zhang Y, Li P, Wang K. The functional roles of exosomal long non-coding RNAs in cancer. Cell Mol Life Sci. 2019 Jun;76(11):2059–76. Sun F, Wu K, Yao Z, Mu X, Zheng Z, Sun M, et al. Long noncoding RNA LINC00963 induces NOP2 expression by sponging tumor suppressor miR-542-3p to promote metastasis in prostate cancer. Aging. 2020 Jun 17;12(12):11500–16. Liu Y, Yang B, Su Y, Xiang Q, Li Q. Downregulation of long noncoding RNA LINC00683 associated with unfavorable prognosis in prostate cancer based on TCGA. J Cell Biochem. 2019 Aug;120(8):14165–74. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017 Jul 3;45(W1):W98–102. Huang Y, Wang X, Zheng Y, Chen W, Zheng Y, Li G, et al. Construction of an mRNA-miRNA-lncRNA network prognostic for triple-negative breast cancer. Aging. 2021 Jan 3;13(1):1153–75. Paraskevopoulou MD, Vlachos IS, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T, et al. DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 2016 Jan 4;44(D1):D231–8. Orlandella FM, Mariniello RM, Iervolino PLC, Imperlini E, Mandola A, Verde A, et al. miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA. Endocrine. 2019 Sep;65(3):582–94. Tang X, Ding Y, Wang X, Wang X, Zhao L, Bi H. miR-650 promotes non-small cell lung cancer cell proliferation and invasion by targeting ING4 through Wnt-1/β-catenin pathway. Oncol Lett. 2019 Nov;18(5):4621–8. Jin S, Li X, Dai Y, Li C, Wang D. NF-κB-mediated miR-650 plays oncogenic roles and activates AKT/ERK/NF-κB pathways by targeting RERG in glioma cells. Cell Oncol. 2020 Dec;43(6):1035–48. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015 Aug 12;4:e05005. Wang K, Zhu TN, Zhao RJ. Filamin A regulates EGFR/ERK/Akt signaling and affects colorectal cancer cell growth and migration. Mol Med Rep. 2019 Oct;20(4):3671–8. Wang YZ, Wong YC. Oncogenes and tumor suppressor genes in prostate cancer: a review. Urol Oncol. 1997 Mar–Apr;3(2):41–6. Shang Z, Yu J, Sun L, Tian J, Zhu S, Zhang B, et al. LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex. Nucleic Acids Res. 2019 May 7;47(8):4211–25. Wu M, Huang Y, Chen T, Wang W, Yang S, Ye Z, et al. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis. J Cell Mol Med. 2019 Jan;23(1):29–38. Zhang Y, Guo S, Wang S, Li X, Hou D, Li H, et al. LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7A11 signaling. Ecotoxicol Environ Saf. 2021 Sep 1;220:112376. Tang Q, Li Z, Han W, Cheng S, Wang Y. High expression of lncRNA SNHG1 in prostate cancer patients and inhibition of SNHG1 suppresses cell proliferation and promotes apoptosis. Indian J Pathol Microbiol. 2020 Oct–Dec;63(4):575–80. Lang C, Yin C, Lin K, Li Y, Yang Q, Wu Z, et al. m(6 A modification of lncRNA PCAT6 promotes bone metastasis in prostate cancer through IGF2BP2-mediated IGF1R mRNA stabilization. Clin Transl Med. 2021 Jun;11(6):e426. Liao B, Chen S, Li Y, Yang Z, Yang Y, Deng X, et al. LncRNA BLACAT1 promotes proliferation, migration and invasion of prostate cancer cells via regulating miR-29a-3p/DVL3 Axis. Technol Cancer Res Treat. 2021 Jan–Dec;20:1533033820972342. Saha S, Kiran M, Kuscu C, Chatrath A, Wotton D, Mayo MW, et al. Long noncoding RNA DRAIC inhibits prostate cancer progression by interacting with IKK to inhibit NF-κB activation. Cancer Res. 2020 Mar 1;80(5):950–63. Cheng G, Song Z, Liu Y, Xiao H, Ruan H, Cao Q, et al. Long noncoding RNA SNHG12 indicates the prognosis of prostate cancer and accelerates tumorigenesis via sponging miR-133b. J Cell Physiol. 2020 Feb;235(2):1235–46. Li DS, Ainiwaer JL, Sheyhiding I, Zhang Z, Zhang LW. Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. Eur Rev Med Pharmacol Sci. 2016 Jun;20(11):2285–95. Edlich F. BCL-2 proteins and apoptosis: recent insights and unknowns. Biochem Biophys Res Commun. 2018 May 27;500(1):26–34. Yan K, Hou L, Liu T, Jiao W, Ma Q, Fang Z, et al. lncRNA OGFRP1 functions as a ceRNA to promote the progression of prostate cancer by regulating SARM1 level via miR-124-3p. Aging. 2020 May 19;12(10):8880–92. Hao H, Chen H, Xie L, Liu H, Wang D. LncRNA KCNQ1OT1 promotes proliferation, invasion and metastasis of prostate cancer by regulating miR-211-5p/CHI3L1 pathway. Onco Targets Ther. 2021;14:1659–71. Jiang Y, Zhao H, Chen Y, Li K, Li T, Chen J, et al. Exosomal long noncoding RNA HOXD-AS1 promotes prostate cancer metastasis via miR-361-5p/FOXM1 axis. Cell Death Dis. 2021 Dec 4;12(12):1129. Zuo ZH, Yu YP, Ding Y, Liu S, Martin A, Tseng G, et al. Oncogenic activity of miR-650 in prostate cancer is mediated by suppression of CSR1 expression. Am J Pathol. 2015 Jul;185(7):1991–9. Han LL, Yin XR, Zhang SQ. miR-650 promotes the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by directly inhibiting LATS2 expression. Cell Physiol Biochem. 2018;51(3):1179–92. Tian ZQ, Shi JW, Wang XR, Li Z, Wang GY. New cancer suppressor gene for colorectal adenocarcinoma: filamin A. World J Gastroenterol. 2015 Feb 21;21(7):2199–205. Xu C, Yu X, Zhu Y, Cai Z, Yu L, Lin Y, et al. Overexpression of calpain-1 predicts poor outcome in patients with colorectal cancer and promotes tumor cell progression associated with downregulation of FLNA. Oncol Rep. 2019 Jun;41(6):3424–34. Zhang Y, Zhu T, Liu J, Liu J, Gao D, Su T, et al. FLNa negatively regulated proliferation and metastasis in lung adenocarcinoma A549 cells via suppression of EGFR. Acta Biochim Biophys Sin. 2018 Feb 1;50(2):164–70. Guo Y, Li M, Bai G, Li X, Sun Z, Yang J, et al. Filamin A inhibits tumor progression through regulating BRCA1 expression in human breast cancer. Oncol Lett. 2018 Nov;16(5):6261–6. Liu S, Wang W, Zhao Y, Liang K, Huang Y. Identification of potential key genes for pathogenesis and prognosis in prostate cancer by integrated analysis of gene expression profiles and the cancer genome atlas. Front Oncol. 2020;10:809. Narain NR, Diers AR, Lee A, Lao S, Chan JY, Schofield S, et al. Identification of Filamin-A and -B as potential biomarkers for prostate cancer. Future Sci OA. 2017 Mar;3(1):FSO161. Sun GG, Lu YF, Zhang J, Hu WN. Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion. Tumour Biol. 2014 Apr;35(4):3819–26. Katzenwadel A, Wolf P. Androgen deprivation of prostate cancer: leading to a therapeutic dead end. Cancer Lett. 2015 Oct 10;367(1):12–7. Article / Publication Details

Received: July 19, 2022
Accepted: February 21, 2023
Published online: April 11, 2023

Number of Print Pages: 13
Number of Figures: 6
Number of Tables: 2

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.